# Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines

> **NCT05059587** · PHASE3 · COMPLETED · sponsor: **Medytox Korea** · enrollment: 318 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **DRUG:** MBA-P01
- **DRUG:** BOTOX

## Key facts

- **NCT ID:** NCT05059587
- **Lead sponsor:** Medytox Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-30
- **Primary completion:** 2021-12-29
- **Final completion:** 2022-03-29
- **Target enrollment:** 318 (ACTUAL)
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05059587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05059587, "Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05059587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*